News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II
MediciNova, Inc. To Present Data On MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis (IPF) During The 18th International Colloquium On Lung And Airway Fibrosis (ICLAF) 9/2/2014
Conatus Pharmaceuticals Inc. Initiates Phase 2 Trial In Patients With Liver Cirrhosis And Separate Open Label Phase 2 Trial In Cirrhosis Patients With Portal Hypertension 9/2/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Adolescents With ADHD 9/2/2014
Cellular Biomedicine Group (CBMG) Launches Clinical Research Study For Cartilage Defect Stem Cell Therapy 9/2/2014
Nuvilex (NVLX) Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-In-A-Box® Treatment For Pancreatic Cancer 9/2/2014
Promedior Receives U.S. Orphan Drug Designation For PRM-151 For The Treatment Of Myelofibrosis 9/2/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Completes Enrollment In Randomized Phase 2 Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 9/2/2014
VentiRx Pharmaceuticals, Inc. Announces Fast Track Designation Granted For Motolimod (VTX-2337), A Novel Immunotherapy For Women With Ovarian Cancer 9/2/2014
Xention Limited Commences First Phase 2 Study Of XEN-D0103 In Atrial Fibrillation 9/2/2014
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer Inc. (PFE) Bid; Start Of New Cancer Trial 8/29/2014
Dezima Pharma Reports Positive Results In Its Phase 2b TULIP Trial With CETP Inhibitor TA-8995 In Dyslipidemia 8/29/2014
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014
Pfizer Inc. (PFE)’s Investigational Vaccine Candidate For Clostridium Difficile Receives FDA Fast Track Designation 8/28/2014
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 8/28/2014
Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation 8/28/2014
Auxilium Pharmaceuticals (AUXL) To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 8/28/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
AVANIR Pharmaceuticals (AVNR) Announces Initiation Of Phase 2 Study Of AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 8/26/2014
Ruthigen Receives Recommendation From Data Monitoring Committee To Initiate Phase 1/2 Human Clinical Trial Of RUT58-60 8/26/2014
Profil Institute for Clinical Research, Inc. Reaches Milestone In Early Phase Clinical Research For Diabetes 8/26/2014
Anavex Life Sciences Corp. (AVXL.OB) Selects The Alfred Hospital In Melbourne, Australia As Lead Site For Phase 2a Alzheimer's Clinical Trial 8/26/2014
U.S. Army Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of PTSD With The NeuroSigma, Inc. eTNS System 8/25/2014
Pradaxa® (dabigatran etexilate mesylate) Data To Be Presented At European Society of Cardiology Congress 2014 8/25/2014
Auxilium Pharmaceuticals (AUXL) Drug Found Effective Against Cellulite In Phase 2 Study 8/22/2014
Look Out Auxilium Pharmaceuticals (AUXL), BioSpecifics Technologies Corporation (BSTC) Also Touts Positive Data From Phase 2a Study Of CCH For Cellulite 8/22/2014
NovaBay Pharmaceuticals, Inc. (NBY) Reports NVC-422 Missed Endpoints In Phase 2 Study 8/21/2014
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type 2 Diabetes In Phase IIb Study On BTI-320 In The U.S. 8/20/2014
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014
MediciNova, Inc. Shows Off Positive Phase 2a Study Of Ibudilast 8/19/2014
iCo Therapeutics Inc. Announces Positive Oral Amphotericin B Study Results 8/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
Celator Pharmaceuticals, Inc. Initiates Pharmacokinetic And Pharmacodynamics Clinical Study Of CPX-351 8/19/2014
DelMar Pharmaceuticals Provides Update On Glioblastoma Clinical Trial And Results Of Warrant Tender Offer 8/19/2014
Innate Immunotherapeutics’s Phase 2B Clinical Trial On SPMS To Start Recruiting Patients Following Perth Site Obtaining Ethics Approval 8/19/2014
Blanchette Rockefeller Neurosciences Institute Release: Human Brain Deficits Of PKCe: Targeted For Alzheimer's Disease Therapeutic And Diagnostic Trials 8/18/2014
Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc. 8/18/2014
Egalet Announces Successful End-Of-Phase 2 Meeting With The FDA For Egalet-002 8/18/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Publication By KaloBios Pharmaceuticals, Inc. (KBIO) And Collaborators Shows EphA3 As Target For Highly Selective Anticancer Therapy 8/14/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study 8/14/2014
Ohr Pharmaceutical (OHRP) Announces Additional Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data In Wet-AMD; The IMPACT Study 8/13/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Cellular Biomedicine Group (CBMG) Completes Patient Treatment In Phase 2b Clinical Trial For Rejoin™ Therapy For Knee Osteoarthritis 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Esperion Therapeutics, Inc. (ESPR) Provides Etc-1002 Development Program Update; Reports Second Quarter 2014 Financial Results 8/12/2014
Biodel Inc. (BIOD)'s Insulin Drug Found Effective In Phase 2 Trial 8/11/2014
Ohr Pharmaceutical (OHRP) Announces Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data in Retinal Vein Occlusion 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Mirati Therapeutics  (MRTX) Receives Orphan Designation From U.S. FDA For Mocetinostat In Diffuse Large B-Cell Lymphoma 8/11/2014
Celladon Corporation Announces Trial To Investigate MYDICAR In Patients With Heart Failure And LVAD 8/11/2014
Xenetic Biosciences Announces Ongoing Safety And Efficacy Data From Phase 2 Trial Of Erepoxen(R) 8/11/2014
BioSpecifics Technologies Corporation (BSTC) Announces Initiation Of Phase 2 Clinical Study Of CCH For Treatment Of Lipoma 8/8/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Oral Presentation Of CytRx Corporation (CYTR)’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology 8/7/2014
Symphogen A/S Release: Sym004 Advances Into Two New Clinical Trials And Receives Milestone Payments 8/7/2014
Neurovance Completes Enrollment In Human Abuse Liability Study For Centanafadine (Formerly Called EB-1020) For Adult ADHD 8/7/2014
San Diego's Cytori Therapeutics, Inc. (CYTX) Crashes As Safety Concerns Suspend Athena Trials 8/7/2014
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001 8/6/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Cara Therapeutics, Inc. (CARA) Initiates Proof-Of-Concept Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 8/6/2014
Synthetic Biologics, Inc. (SYN) On Track To Initiate Clinical Program For SYN-004 To Protect Against C. difficile 8/5/2014
Atox Bio Release: AB103 Granted Orphan Medicinal Product Designation In The European Union For The Treatment Of Necrotizing Soft Tissue Infections (NSTI) 8/5/2014
Ophthotech Corporation (OPHT) Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration 8/5/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce First Patient Dosed In Phase 2 Study Of VPD-737 In Prurigo Nodularis 8/4/2014
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014
Final Patient Treated In NeuralStem Inc. Phase II ALS Stem Cell Trial 8/4/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies 8/4/2014
NPS Pharmaceuticals, Inc. (NPSP) Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH) 8/4/2014
Novartis AG (NVS) Malaria Pill KAE609 Shows Promise As Best Drugs Fail 8/1/2014
Biota Pharmaceuticals, Inc. (BOTA) Stock Crashes As Influenza Drug Laninamivir Octanoate Fails Mid-Stage Trial; Stock Down -20.54% At 11:37AM ET 8/1/2014
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014
Expanded Data On Disability And Cognitive Improvements In Phase 2 Study Of Synthetic Biologics, Inc. (SYN)' Trimesta™ In Multiple Sclerosis To Be Presented At 2014 Joint ACTRIMS-ECTRIMS Meeting 7/31/2014
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014
Kala Pharmaceuticals Initiates Phase 2 Clinical Trial To Evaluate LE-MPP (KPI-121) In Patients With Retinal Vein Occlusion And Diabetic Macular Edema 7/31/2014
Immune Pharmaceuticals, Inc. Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 7/30/2014
RXi Pharmaceuticals (RXII) Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars 7/30/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
EMD Serono Initiates Phase 2 Study Of Anti-PD-L1 Antibody MSB0010718C In Metastatic Merkel Cell Carcinoma 7/29/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
Neurotrope Initiates Phase 2a Study Of Bryostatin For The Treatment Of Alzheimer's Disease - Doses First Patients 7/29/2014
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
Medivir AB (MVRBF): Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day 7/28/2014
Phase 2 COSMOS Study Results Published In The Lancet Demonstrate Efficacy And Safety Of Janssen’s Once-Daily Simeprevir In All Oral 12-Week Combination With Sofosbuvir For Genotype 1 Chronic Hepatitis C 7/28/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer 7/28/2014
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014
Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014
Celsion Corporation (CLSN) Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study In Breast Cancer 7/24/2014
Innapharma: Completion Of Target Enrollment In The Phase 2 EffiKIR Trial 7/24/2014
Inovio Pharmaceuticals (INO) HPV Immunotherapy Achieves Primary Efficacy Endpoint In Randomized Phase 2 Cervical Dysplasia Trial 7/23/2014
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/23/2014
Biotron Limited (BIT:AU) BIT225 Reverses HIV-Induced Impairment Of The Immune System 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China 7/21/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014
Anavex Life Sciences Corp. (AVXL.OB) Achieves Key Milestone As It Secures Cgmp Manufacturing For Drug Candidate Trial Supplies 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a) 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
Synergy Pharmaceuticals Completes Patient Enrollment For Its SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Targacept, Inc. (TRGT) Stops Alzheimer's Drug Trial After It Fails Phase 2b Trial 7/16/2014
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014
Adynxx Initiates Phase 2 Dose-Ranging Study Of AYX1, Lead Compound For The Prevention Of Post-Surgical Pain 7/16/2014
Resolve Therapeutics Initiates Phase 2 Clinical Study In SLE 7/16/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
GenSpera Presents G-202 HCC Clinical Trial Update At 5th Asia-Pacific Primary Liver Cancer Expert Meeting 7/15/2014
Amarantus BioSciences, Inc. Announces Positive Clinical Performance And 7-Year Longitudinal Data Poster Presentations For Lympro Test® At AAIC 2014 7/15/2014
CellAct Pharma Receives Orphan Drug Designation In EU For CAP7.1 In Biliary Tract Cancers 7/15/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014
Genticel’s Phase 2 Study With ProCervix Passes The Halfway Mark For Patient Recruitment 7/10/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Tames Eczema In Phase 2b Trial 7/10/2014
Cytokinetics, Inc. (CYTK) Announced Additional Results Relating To Tirasemtiv From Pre-Specificed Subgroup Analyses Of BENEFIT-ALS 7/10/2014
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Prader-Willi Syndrome 7/10/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Boehringer Ingelheim Corporation's Breakthrough Cancer Drug Volasertib Effective In Phase 2 Trial 7/9/2014
National Institutes of Health (NIH) Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS Systemnational 7/9/2014
Acasti Pharma Completes Phase 2 Double Blind (TRIFECTA) And Pharmacokinetic Trials 7/9/2014
Adocia Announces Approval To Start A Phase IIa Clinical Study Of Hinsbet®, Its Fast-Acting Human Insulin, In Type 1 Diabetes 7/9/2014
Lexicon Pharmaceuticals, Inc. (LXRX) And Juvenile Diabetes Research Foundation Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes 7/9/2014
480 Biomedical Awarded $1 Million Phase II NHLBI Contract To Advance Bioresorbable Scaffold For Pediatric Pulmonary Artery Stenosis 7/9/2014
Opko Health, Inc.'s Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations In Europe 7/9/2014
NeoStem, Inc. Presents Five-Year Survival Data For Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells At American Society of Clinical Oncology Annual Meeting 7/9/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
PRC Clinical Completes Over 800 Monitoring Visits In Global Phase 2b Neurology Study 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Avraham Pharmaceuticals Ltd. Announces Successful Interim Results In Phase 2b Study Of Ladostigil For The Treatment Of MCI 7/8/2014
CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 7/8/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Patient Enrollment IN U.S. Randomized Phase 2 Pancreatic Cancer Study 7/8/2014
Synergy Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Plecanatide In Irritable Bowel Syndrome With Constipation 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Celladon Corporation Announces New Clinical Development Initiatives For MYDICAR® 7/7/2014
CASI Pharmaceuticals  (ENMD) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma 7/7/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
Amgen (AMGN) Wins FDA Breakthrough Therapy Designation For Investigational BiTE 7/3/2014
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of A Phase 2 Study Of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU 7/1/2014
AVANIR Pharmaceuticals (AVNR) Announces Two Data Presentations Related To Pseudobulbar Affect (PBA) At The Alzheimer's Association International Conference (AAIC) 7/1/2014
Agenus (AGEN) Brain Cancer Vaccine Shows Extended Survival In Phase 2 Final Data Analysis 7/1/2014
Threshold Pharmaceuticals, Inc. (THLD) Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial Of TH-302 In Combination With Pemetrexed In Advanced Non-Squamous Non-Small Cell Lung Cancer 7/1/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment 7/1/2014
Molecular Partners AG Release: Stage 3 Phase 2 Study Of DARPin Abicipar Pegol (Previously MP0112) Supports Progressing To Phase 3 Development Program 7/1/2014
Agenus (AGEN)'s Brain Cancer Vaccine Doubles Survival Rate In Phase 2 Study 7/1/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
Mologen AG (MOLGF.PK): Cancer Immune Therapy MGN1703 Shows Outstanding Long-Term Responses 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS 6/30/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Amunix, Inc. Congratulates Versartis, Inc. (VSAR) On Its Positive Phase 2a Results With VRS-317 6/30/2014
Burzynski Research Institute Announces Presentations At The 16th International Symposium On Pediatric Neuro-Oncology 6/27/2014
Bellerophon Therapeutics Completes Enrollment Of Its Phase 2 Trial Of Inopulse® For Treatment Of Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) 6/27/2014
Coronado Biosciences (CNDO) Reports Topline Results From Investigator Initiated Pilot Study Of TSO In Adults With Autism Spectrum Disorder 6/26/2014
Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society 6/26/2014
Aurinia (ISA.TO) Initiates Phase 2b Clinical Trial Of Voclosporin To Treat Lupus Nephritis 6/26/2014
Nora Pharma Announces Initiation Of Phase 2 RESPONSE Research Study 6/26/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Agenus (AGEN) Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation 6/26/2014
Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury 6/26/2014
Massachusetts' Agenus (AGEN) Touts Positive Phase 2 Data From HerpV Study 6/26/2014
Aerie Pharmaceuticals, Inc. (AERI) Soars As Combo Eye Drug Roclatan Performs Well In Phase 2b Trial; Stock Up +28.29% At Market Close (June 25, 2014) 6/26/2014
Antares Pharma, Inc. (ATRS) Release: Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector 6/25/2014
Synthetic Biologics, Inc. (SYN) Reports That Licensor Cedars-Sinai Medical Center Finds Eradication Of Gut Methane Improves Insulin Sensitivity And Lipid Profiles In Study Of Pre-Diabetic, Obese Patients 6/25/2014
NeuralStem Inc.'s NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder 6/25/2014
GenSpera Releases 2014 Biotechnology Industry Organization (BIO) International Presentation And HCC Clinical Trial Update For G-202 6/25/2014
NovaBiotics Ltd Release: Initiation Of A Phase IIa Clinical Study For Lynovex® In Cystic Fibrosis 6/25/2014
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014
Ohr Pharmaceutical (OHRP) To Host Conference Call And Webcast To Discuss Squalamine Interim Phase 2 Data In Wet-AMD 6/24/2014
Ohr Pharmaceutical (OHRP) Eye Drug Falls Short In Phase 2 Trial 6/24/2014
Versartis, Inc. (VSAR) Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results 6/24/2014



//-->